Blog

Athletic footwear represents a uniquely dense intersection of biomechanics, materials, science, industrial design, and intellectual property law. Unlike many consumer products, modern athletic shoes are simultaneously performance devices, brand signifiers, and regulated consumer goods, giving rise to unusually complex patent portfolios. Over the past decade, and with increasing intensity in recent years, footwear companies have expanded patent protection beyond traditional outsole patterns and upper configurations into integrated mechanical systems, advanced polymeric materials, and digitally enabled manufacturing methods.

The global insurance industry is experiencing a profound technological transition. Artificial intelligence, predictive analytics, telematics, IoT-enabled risk monitoring, cyber-defense platforms, and automated claims assessment tools now sit at the core of underwriting and claims operations. As these capabilities grow more sophisticated, intellectual property, especially patents, has become essential for protecting these technologies and securing competitive advantage. Major insurers such as Travelers, Aetna, Chubb, Berkshire Hathaway, AIG, and AXA increasingly view their digital platforms not merely as operational tools, but as proprietary assets requiring legal protection. Patent strategy now intersects directly with insurance law, regulatory frameworks, and innovation agendas, creating a landscape in which IP strategy must be aligned with compliance and business needs.

Abstract — A Modest Patent Law Proposal
This paper examines the landmark Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., 574 U.S. 318 (2015), which reshaped U.S. patent claim-construction standards by requiring appellate courts to apply a “clear error” review to factual findings. Using the Teva litigation’s ambiguity over polymer molecular weight definitions in Copaxone® (glatiramer acetate) as a central example, the paper highlights how technical imprecision and inconsistent expert testimony can distort both prosecution and litigation outcomes. It proposes a modernized framework for biotechnology patent review that combines increased USPTO examiner time, AI-based prior-art analysis, scientific peer-review resources, and a new appellate evidentiary standard—“scientific veracity.” Drawing upon legal precedents including Markman v. Westview Instruments and Nautilus v. Biosig Instruments, as well as polymer science authorities such as Flory (1953) and ASTM/ISO standards, this proposal seeks to ensure that patents involving complex scientific subject matter rest on empirically sound and legally robust foundations—thereby strengthening innovation, investment confidence, and public trust in U.S. intellectual property law.